Allergen Immunotherapy in Allergic Patients

Allergic Rhinitis Clinical Trial

Official title:

Long Term Follow up in Patients Using Immunotherapy: Efficacy and Impact on Quality of Life

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02040974
• Other study ID #: 1978
• Status: Recruiting
• Phase: N/A
• First received: January 16, 2014
• Last updated: January 17, 2014
• Start date: January 2007
• Est. completion date: September 2014

Study information

• Verified date: January 2014
• Source: Istanbul University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ethics Committee
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Our aim was to evaluate the effectiveness of subcutaneous allergen immunotherapy with the symptom scores (RSS), visual analog scale (VAS) and medication scores (MS) and the impact on quality of life with rhinoconjunctivitis quality of life questionnaire (RQLQ) in allergic rhinitis patients sensitized to different allergens. Also the development of new sensitizations and asthma during the immunotherapy were determined.

Description:

Allergic rhinitis patients sensitized to at least one common aero-allergen who completed a three or five year period of allergen immunotherapy in our outpatient clinic between 2002-2013 were enrolled in the study and patients with allergic rhinitis who received only medical treatment were chosen as the control group. Patients were separated in two groups according to sensitization patterns including pollens or house dust mites. All patients were evaluated before immunotherapy, in the first and the fifth years of treatment and two years after the treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• allergic rhinitis/asthma

Exclusion Criteria:

• pregnancy,

• malignity,

• autoimmunity

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Allergic Rhinitis

Locations

Country	Name	City	State
Turkey	Istanbul Faculty of Medicine	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The improvent of quality of life		5 years	No